Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

I-MOVE-COVID-19 primary care study team; Esther Kissling; Mariette Hooiveld; Virginia Sandonis Martín; Iván Martínez-Baz; Naoma William; Ana Maria Vilcu; Clara Mazagatos; Lisa Domegan; Simon de Lusignan; Adam Meijer; Ausenda Machado; Mia Brytting; Itziar Casado; Josephine L.K. Murray; Sylvie Belhillil; Amparo Larrauri; Joan O'Donnell; Ruby Tsang; Marit de Lange; Ana Paula Rodrigues; Maximilian Riess; Jesús Castilla; Mark Hamilton; Alessandra Falchi; Francisco Pozo; Linda Dunford; Jade Cogdale; Tessa Jansen; Raquel Guiomar; Theresa Enkirch; Cristina Burgui; Debbie Sigerson; Thierry Blanchon; Eva María Martínez Ochoa; Jeff Connell; Joanna Ellis; Rianne van Gageldonk-Lafeber; Irina Kislaya; Angela Mc Rose; Marta Valenciano

doi:10.2807/1560-7917.ES.2021.26.29.2100670

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

I-MOVE-COVID-19 primary care study team, Esther Kissling, Mariette Hooiveld, Virginia Sandonis Martín, Iván Martínez-Baz, Naoma William, Ana Maria Vilcu, Clara Mazagatos, Lisa Domegan, Simon de Lusignan, Adam Meijer, Ausenda Machado, Mia Brytting, Itziar Casado, Josephine L.K. Murray, Sylvie Belhillil, Amparo Larrauri, Joan O'Donnell, Ruby Tsang, Marit de LangeAna Paula Rodrigues, Maximilian Riess, Jesús Castilla, Mark Hamilton, Alessandra Falchi, Francisco Pozo, Linda Dunford, Jade Cogdale, Tessa Jansen, Raquel Guiomar, Theresa Enkirch, Cristina Burgui, Debbie Sigerson, Thierry Blanchon, Eva María Martínez Ochoa, Jeff Connell, Joanna Ellis, Rianne van Gageldonk-Lafeber, Irina Kislaya, Angela Mc Rose, Marta Valenciano

Research output: Contribution to journal › Article › peer-review

37 Citations (Scopus)

9 Downloads (Pure)

Abstract

We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.

Original language	English
Article number	2100670
Number of pages	7
Journal	Eurosurveillance
Volume	26
Issue number	29
DOIs	https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670
Publication status	Published - 22 Jul 2021

Bibliographical note

Funding Information: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673.
Professor de Lusignan has received grants not directly relating to this work, from AstraZeneca, GSK, Sanofi, Seqirus and Takeda for vaccine-related research and has been a member of advisory boards for AstraZeneca, Sanofi and Seqirus.

Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Publisher Copyright: Citation style for this article: Kissling Esther, Hooiveld Mariette, Sandonis Martín Virginia, Martínez-Baz Iván, William Naoma, Vilcu Ana-Maria, Mazagatos Clara, Domegan Lisa, de Lusignan Simon, Meijer Adam, Machado Ausenda, Brytting Mia, Casado Itziar, Murray Josephine-L K., Belhillil Sylvie, Larrauri Amparo, O’Donnell Joan, Tsang Ruby, de Lange Marit, Rodrigues Ana Paula, Riess Maximilian, Castilla Jesús, Hamilton Mark, Falchi Alessandra, Pozo Francisco, Dunford Linda, Cogdale Jade, Jansen Tessa, Guiomar Raquel, Enkirch Theresa, Burgui Cristina, Sigerson Debbie, Blanchon Thierry, Martínez Ochoa Eva María, Connell Jeff, Ellis Joanna, van Gageldonk-Lafeber Rianne, Kislaya Irina, Rose Angela MC, Valenciano Marta, I-MOVE-COVID-19 primary care study team. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Euro Surveill. 2021;26(29):pii=2100670. https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670

DOI: https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670

Keywords

COVID-19
Europe
SARS-CoV-2
multicentre study
test-negative design
vaccine effectiveness

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2807/1560-7917.ES.2021.26.29.2100670Licence: CC BY

Kissling2021VaccineEffectivenessAgainstSymptomaticSARS-CoV-2InfectionInAdultsAged65YearsAndOlderInPrimaryCareEuroSurveillFinal published version, 144 KBLicence: CC BY

Cite this

I-MOVE-COVID-19 primary care study team, Kissling, E., Hooiveld, M., Sandonis Martín, V., Martínez-Baz, I., William, N., Vilcu, A. M., Mazagatos, C., Domegan, L., de Lusignan, S., Meijer, A., Machado, A., Brytting, M., Casado, I., Murray, J. L. K., Belhillil, S., Larrauri, A., O'Donnell, J., Tsang, R., ... Valenciano, M. (2021). Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Eurosurveillance, 26(29), Article 2100670. https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670

@article{330a4711ae134a5698bd3eacc1d6df58,

title = "Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021",

abstract = "We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.",

keywords = "COVID-19, Europe, SARS-CoV-2, multicentre study, test-negative design, vaccine effectiveness",

author = "{I-MOVE-COVID-19 primary care study team} and Esther Kissling and Mariette Hooiveld and {Sandonis Mart{\'i}n}, Virginia and Iv{\'a}n Mart{\'i}nez-Baz and Naoma William and Vilcu, {Ana Maria} and Clara Mazagatos and Lisa Domegan and {de Lusignan}, Simon and Adam Meijer and Ausenda Machado and Mia Brytting and Itziar Casado and Murray, {Josephine L.K.} and Sylvie Belhillil and Amparo Larrauri and Joan O'Donnell and Ruby Tsang and {de Lange}, Marit and Rodrigues, {Ana Paula} and Maximilian Riess and Jes{\'u}s Castilla and Mark Hamilton and Alessandra Falchi and Francisco Pozo and Linda Dunford and Jade Cogdale and Tessa Jansen and Raquel Guiomar and Theresa Enkirch and Cristina Burgui and Debbie Sigerson and Thierry Blanchon and {Mart{\'i}nez Ochoa}, {Eva Mar{\'i}a} and Jeff Connell and Joanna Ellis and {van Gageldonk-Lafeber}, Rianne and Irina Kislaya and Rose, {Angela Mc} and Marta Valenciano",

note = "Funding Information: This project has received funding from the European Union{\textquoteright}s Horizon 2020 research and innovation programme under grant agreement No 101003673. Professor de Lusignan has received grants not directly relating to this work, from AstraZeneca, GSK, Sanofi, Seqirus and Takeda for vaccine-related research and has been a member of advisory boards for AstraZeneca, Sanofi and Seqirus. Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made. Publisher Copyright: Citation style for this article: Kissling Esther, Hooiveld Mariette, Sandonis Mart{\'i}n Virginia, Mart{\'i}nez-Baz Iv{\'a}n, William Naoma, Vilcu Ana-Maria, Mazagatos Clara, Domegan Lisa, de Lusignan Simon, Meijer Adam, Machado Ausenda, Brytting Mia, Casado Itziar, Murray Josephine-L K., Belhillil Sylvie, Larrauri Amparo, O{\textquoteright}Donnell Joan, Tsang Ruby, de Lange Marit, Rodrigues Ana Paula, Riess Maximilian, Castilla Jes{\'u}s, Hamilton Mark, Falchi Alessandra, Pozo Francisco, Dunford Linda, Cogdale Jade, Jansen Tessa, Guiomar Raquel, Enkirch Theresa, Burgui Cristina, Sigerson Debbie, Blanchon Thierry, Mart{\'i}nez Ochoa Eva Mar{\'i}a, Connell Jeff, Ellis Joanna, van Gageldonk-Lafeber Rianne, Kislaya Irina, Rose Angela MC, Valenciano Marta, I-MOVE-COVID-19 primary care study team. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Euro Surveill. 2021;26(29):pii=2100670. https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670 DOI: https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670",

year = "2021",

month = jul,

day = "22",

doi = "10.2807/1560-7917.ES.2021.26.29.2100670",

language = "English",

volume = "26",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control",

number = "29",

}

I-MOVE-COVID-19 primary care study team, Kissling, E, Hooiveld, M, Sandonis Martín, V, Martínez-Baz, I, William, N, Vilcu, AM, Mazagatos, C, Domegan, L, de Lusignan, S, Meijer, A, Machado, A, Brytting, M, Casado, I, Murray, JLK, Belhillil, S, Larrauri, A, O'Donnell, J, Tsang, R, de Lange, M, Rodrigues, AP, Riess, M, Castilla, J, Hamilton, M, Falchi, A, Pozo, F, Dunford, L, Cogdale, J, Jansen, T, Guiomar, R, Enkirch, T, Burgui, C, Sigerson, D, Blanchon, T, Martínez Ochoa, EM, Connell, J, Ellis, J, van Gageldonk-Lafeber, R, Kislaya, I, Rose, AM & Valenciano, M 2021, 'Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021', Eurosurveillance, vol. 26, no. 29, 2100670. https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. / I-MOVE-COVID-19 primary care study team; Kissling, Esther; Hooiveld, Mariette et al.
In: Eurosurveillance, Vol. 26, No. 29, 2100670, 22.07.2021.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care

T2 - I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

AU - I-MOVE-COVID-19 primary care study team

AU - Kissling, Esther

AU - Hooiveld, Mariette

AU - Sandonis Martín, Virginia

AU - Martínez-Baz, Iván

AU - William, Naoma

AU - Vilcu, Ana Maria

AU - Mazagatos, Clara

AU - Domegan, Lisa

AU - de Lusignan, Simon

AU - Meijer, Adam

AU - Machado, Ausenda

AU - Brytting, Mia

AU - Casado, Itziar

AU - Murray, Josephine L.K.

AU - Belhillil, Sylvie

AU - Larrauri, Amparo

AU - O'Donnell, Joan

AU - Tsang, Ruby

AU - de Lange, Marit

AU - Rodrigues, Ana Paula

AU - Riess, Maximilian

AU - Castilla, Jesús

AU - Hamilton, Mark

AU - Falchi, Alessandra

AU - Pozo, Francisco

AU - Dunford, Linda

AU - Cogdale, Jade

AU - Jansen, Tessa

AU - Guiomar, Raquel

AU - Enkirch, Theresa

AU - Burgui, Cristina

AU - Sigerson, Debbie

AU - Blanchon, Thierry

AU - Martínez Ochoa, Eva María

AU - Connell, Jeff

AU - Ellis, Joanna

AU - van Gageldonk-Lafeber, Rianne

AU - Kislaya, Irina

AU - Rose, Angela Mc

AU - Valenciano, Marta

N1 - Funding Information: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. Professor de Lusignan has received grants not directly relating to this work, from AstraZeneca, GSK, Sanofi, Seqirus and Takeda for vaccine-related research and has been a member of advisory boards for AstraZeneca, Sanofi and Seqirus. Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made. Publisher Copyright: Citation style for this article: Kissling Esther, Hooiveld Mariette, Sandonis Martín Virginia, Martínez-Baz Iván, William Naoma, Vilcu Ana-Maria, Mazagatos Clara, Domegan Lisa, de Lusignan Simon, Meijer Adam, Machado Ausenda, Brytting Mia, Casado Itziar, Murray Josephine-L K., Belhillil Sylvie, Larrauri Amparo, O’Donnell Joan, Tsang Ruby, de Lange Marit, Rodrigues Ana Paula, Riess Maximilian, Castilla Jesús, Hamilton Mark, Falchi Alessandra, Pozo Francisco, Dunford Linda, Cogdale Jade, Jansen Tessa, Guiomar Raquel, Enkirch Theresa, Burgui Cristina, Sigerson Debbie, Blanchon Thierry, Martínez Ochoa Eva María, Connell Jeff, Ellis Joanna, van Gageldonk-Lafeber Rianne, Kislaya Irina, Rose Angela MC, Valenciano Marta, I-MOVE-COVID-19 primary care study team. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Euro Surveill. 2021;26(29):pii=2100670. https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670 DOI: https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670

PY - 2021/7/22

Y1 - 2021/7/22

N2 - We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.

AB - We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.

KW - COVID-19

KW - Europe

KW - SARS-CoV-2

KW - multicentre study

KW - test-negative design

KW - vaccine effectiveness

UR - http://www.scopus.com/inward/record.url?scp=85112153857&partnerID=8YFLogxK

U2 - 10.2807/1560-7917.ES.2021.26.29.2100670

DO - 10.2807/1560-7917.ES.2021.26.29.2100670

M3 - Article

C2 - 34296676

AN - SCOPUS:85112153857

SN - 1025-496X

VL - 26

JO - Eurosurveillance

JF - Eurosurveillance

IS - 29

M1 - 2100670

ER -

I-MOVE-COVID-19 primary care study team, Kissling E, Hooiveld M, Sandonis Martín V, Martínez-Baz I, William N et al. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Eurosurveillance. 2021 Jul 22;26(29):2100670. doi: 10.2807/1560-7917.ES.2021.26.29.2100670

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this